University College London researchers found that fat-derived molecules called epoxy-oxylipins limit expansion of intermediate monocytes. Blocking the enzyme that breaks these molecules down raised their levels in volunteers, reduced harmful immune-cell changes, and hastened pain resolution.
Epoxy-oxylipins act as a biological brake that helps shut down inflammation by preventing expansion of intermediate monocytes.
Blocking soluble epoxide hydrolase (sEH) with the drug GSK2256294 increased epoxy-oxylipin levels in human volunteers, reduced intermediate monocytes in blood and tissue, and sped pain relief.
One epoxy-oxylipin, 12,13-EpOME, suppresses the p38 MAPK signaling pathway that drives monocyte transformation associated with prolonged inflammation.
# What the study found Researchers at University College London identified a natural mechanism that helps the immune system switch off inflammation. Small fat-derived molecules called epoxy-oxylipins act as a brake on immune activity by limiting the growth of intermediate monocytes, a white blood cell type linked to prolonged inflammatory responses.
# How the finding was tested in people To study the shutdown process directly, volunteers received tiny injections of UV-killed E. coli in the forearm to trigger a short-lived inflammatory response without causing infection. The study used two treatment timings to test whether boosting epoxy-oxylipins could prevent or reverse harmful immune changes:
# Key outcomes in volunteers Both prophylactic and therapeutic dosing produced similar effects. Raising epoxy-oxylipins via sEH inhibition:
# Molecular mechanism identified Laboratory work identified 12,13-EpOME, one epoxy-oxylipin, as an active molecule that suppresses the p38 MAPK signaling pathway. p38 MAPK promotes the transformation of monocytes into the intermediate form linked to sustained inflammatory activity. The team confirmed this mechanism with cell experiments and by showing similar effects when volunteers received a drug that directly blocks p38.
# Why this matters for treatment strategies Many current treatments for chronic inflammatory and autoimmune diseases work by broadly suppressing immune functions, which can compromise host defenses. This study points to an alternative approach: strengthen a natural shutdown pathway the body already uses. Enhancing epoxy-oxylipin activity or blocking sEH could reduce harmful immune-cell expansion and shorten pain without wholesale immunosuppression.
# What the study does not claim
# Immediate next steps implied by the study
# Bottom line The study reveals a previously underappreciated natural brake on inflammation mediated by epoxy-oxylipins and shows that blocking sEH in people raises those molecules, reduces a cell type tied to chronic inflammation, and speeds pain relief. The pathway offers a targeted strategy that could complement or replace broad immunosuppression in future anti-inflammatory therapies.
The findings offer new insights that could help guide the development of future therapies. A protein called human resistin may help flip on one of the immune system’s most powerful inflammatory switches. Researchers at Johns Hopkins Medicine found that resistin can activate a pathway involved in chronic inflammation, a
A 2026 Johns Hopkins study published in PLOS One identified human resistin as a key driver of the NLRP3 inflammasome The post Study Finds a Key Switch Behind Harmful Inflammation appeared first on The Hearty Soul .
Aging may be partly fueled by immune cells losing their ability to clear away damaged, inflammation-promoting cells. Blocking a single receptor restored that cleanup process in mice, reducing inflammation and helping their organs, muscles, and memory remain remarkably youthful.
Scientists discovered that aging cells can use malfunctioning mitochondria to unlock inflammatory genes and keep the immune system stuck in a prolonged state of alert. Blocking one part of this process reduced inflammation and improved healthy aging in mice, suggesting a promising new strategy for fighting age-related
Depression remains one of the most burdensome psychiatric disorders worldwide, yet the molecular events that translate chronic stress into the loss of motivation, low mood, and cognitive dulling characteristic of the illness have remained stubbornly opaque. A new study published in Cellular and Molecular Life Sciences
Scientists found that the 3D organization of DNA is disrupted in several types of brain cells affected by Alzheimer’s disease, altering how important genes are switched on and off. The discovery reveals a previously underexplored layer of the disease that could open new paths for understanding and eventually treating A
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.